Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
Middleman
M N
MN
Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Lush
R M
RM
Sartor
O
O
Reed
E
E
Figg
W D
WD
D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D006801:Humans; D008297:Male; D008967:Molecular Biology; D009154:Mutation / Q000235:genetics; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011944:Receptors, Androgen / Q000187:drug effects / Q000235:genetics
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D011944:Receptors, Androgen